 |
| 17-May-13 | Initiated |
UBS |
Neutral |
$290 |
|
| 06-May-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$270 → $286 |
|
| 06-May-13 | Reiterated |
Barclays |
Overweight |
$275 → $305 |
|
| 02-May-13 | Reiterated |
Barclays |
Overweight |
$194 → $275 |
|
| 28-Feb-13 | Initiated |
Barclays |
Overweight |
$194 |
|
| 21-Dec-12 | Reiterated |
RBC Capital Mkts |
Outperform |
$171 → $190 |
|
| 14-Feb-12 | Reiterated |
RBC Capital Mkts |
Outperform |
$83 → $130 |
|
| 10-Jan-12 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$56 → $81 |
|
| 05-Dec-11 | Reiterated |
Brean Murray |
Buy |
$78 → $67 |
|
| 28-Jul-11 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$70 → $70 |
|
| 09-May-11 | Reiterated |
Needham |
Buy |
$49 → $60 |
|
| 29-Apr-11 | Reiterated |
Barclays Capital |
Overweight |
$64 → $72 |
|
| 29-Apr-11 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
$70 → $70 |
|
| 28-Apr-11 | Reiterated |
RBC Capital Mkts |
Outperform |
$48 → $70 |
|
| 28-Apr-11 | Reiterated |
Brean Murray |
Buy |
$67 → $78 |
|
| 27-Apr-11 | Reiterated |
Brean Murray |
Buy |
$57 → $67 |
|
| 27-Apr-11 | Reiterated |
Barclays Capital |
Overweight |
$61 → $64 |
|
| 27-Apr-11 | Initiated |
Boenning & Scattergood |
Outperform |
$58 |
|
| 18-Apr-11 | Reiterated |
Brean Murray |
Buy |
$46 → $57 |
|
| 13-Apr-11 | Reiterated |
Barclays Capital |
Overweight |
$47 → $56 |
|
|
|
| 21-May-13 06:32PM | Regeneron and Sanofi: An Unstoppable Biotech Duo? at Motley Fool |
| 04:12PM | New Drug May Help Some Asthmatics, Study Finds at New York Times |
| 08:52AM | New Asthma Drug Generates Excitement For Patients -- And Its Maker at Forbes |
| 08:15AM | InPlay: Regeneron Pharms and Sanofi and announce publication of positive Phase 2a results of dupilumab in asthma in the New England Journal of Medicine Briefing.com |
| 08:15AM | Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine PR Newswire |
| 08:14AM | Regeneron, Sanofi asthma drug seen as potential game changer at Reuters |
| 20-May-13 07:01PM | On The Fly: After Hours Movers at theflyonthewall.com |
| 06:26PM | Regeneron settles all pending litigation with Roche's Genentech at Reuters |
| 01:50PM | Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 10:00 AM at Seeking Alpha |
| 01:04PM | 5 Stocks Underperforming Today In The Drugs Industry at TheStreet |
| 10:07AM | REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 10:01AM | Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet |
| 09:51AM | 2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling at Seeking Alpha |
| 18-May-13 02:30PM | Will ASCO Unlock Big Value in This Cancer Drug Class? at Motley Fool |
| 17-May-13 06:51PM | IBD 50 Stocks Delivering Strong Earnings, Sales Gains at Investor's Business Daily |
| 03:21AM | Coverage initiated on Regeneron Pharms by UBS Briefing.com |
| 16-May-13 03:38PM | A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street Transcript Wall Street Transcript |
| 09:49AM | Pepper Snapple Group CEO Sells More Than 67K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 09:19AM | S&P 500 Stocks Farthest Above 50-DMAs at Seeking Alpha |
| 08:28AM | Sanofi and Regeneron's Latest Partnership at Motley Fool |
| 07:51AM | The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Zacks |
| 15-May-13 05:19PM | 4 Healthcare Stock Stories Prescribed for Investors at Wall St. Cheat Sheet |
| 05:01PM | Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard at TheStreet |
| 05:00PM | Sanofi/REGN Commence Enrollment Zacks |
| 01:03PM | 3 Stocks Underperforming Today In The Drugs Industry at TheStreet |
| 12:49PM | Cramer: Buy Aqua America, Radian, Regeneron, and These 2 Stocks at Wall St. Cheat Sheet |
| 09:31AM | [video] Cramer's '4 Horsemen of the Apocalypse' for Shorts at CNBC |
| 01:31AM | Sanofi recruits patients for arthritis trials at Reuters |
| 01:00AM | Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) PR Newswire |
| 14-May-13 06:00PM | Jim Cramer's 5 Investing Sweet Spots at CNBC |
| 04:25PM | Why This Stock's Crash is a Buying Opportunity at Motley Fool |
| 09:52AM | [video] Cramer's Six in 60: Monster Beverage, Clorox & More at CNBC |
| 06:10AM | [$$] Biotech Fund: Many Healthy Returns at Barrons.com |
| 13-May-13 11:24AM | Is Regeneron A Value Pick In The Pharma Sector? at Seeking Alpha |
| 08:58AM | NorthStar Realty COO Sells More Than 192K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 11-May-13 11:31AM | The 4 Stocks Driving the S&P 500 Higher at Motley Fool |
| 10-May-13 04:39PM | Cramer: Biotech Makes a Comeback at TheStreet |
| 01:04PM | REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 12:52PM | Biotech Makes a Comeback TheStreet |
| 11:14AM | Regeneron Stock Hits New 52-Week High (REGN) at TheStreet |
| 08:58AM | Comcast Executive VP Sells More Than 23K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 09-May-13 10:28AM | Nailing Big Winners In The Market at Seeking Alpha |
| 09:25AM | Bed Bath & Beyond CFO Sells 125K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 06:00AM | Biotech Is Where the Bucks Are TheStreet |
| 08-May-13 01:22PM | Double-Digit Returns from the Biotechnology Strategy at Motley Fool |
| 10:00AM | Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet |
| 09:30AM | Regeneron Announces Upcoming 2013 Investor Conference Presentations PR Newswire |
| 09:05AM | Regeneron Leads Top 5 Big Cap Stocks By Sales Growth at Investor's Business Daily |
| 07-May-13 10:26AM | Regeneron: Solid Q1 Creates Platform For Further Upside at Seeking Alpha |
| 07:41AM | [$$] Regeneron Set for Eye-Opening Upside at Barrons.com |
| 06-May-13 09:34PM | 3 Healthcare Stock Stories For Monday Investment Wellness at Wall St. Cheat Sheet |
| 05:46PM | How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market at Seeking Alpha |
| 01:04PM | 5 Stocks Dragging In The Health Care Sector at TheStreet |
| 09:46AM | REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online |
| 04-May-13 03:46PM | 5 Healthcare Stocks Heading in Different Directions After Earnings at Wall St. Cheat Sheet |
| 03:22PM | Who Got Rich This Week: Pharma Legend P. Roy Vagelos, Chief Yelper Levchin And More at Forbes |
| 11:30AM | 3 Booming Biotech Companies at Motley Fool |
| 07:00AM | The Best- And Worst-Performing Biotech Stocks, April 26 to May 3 at Forbes |
| 03-May-13 06:58PM | [video] No Huddle Offense: What's Working In Pharma at CNBC +7.05% |
| 06:04PM | Regeneron Pharma raises sales forecast for Eylea AP |
| 05:25PM | Regeneron Earnings Soar As Eylea Sales Skyrocket Investor's Business Daily |
| 05:00PM | Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Winner at TheStreet |
| 04:33PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:18PM | Fridays movers: Regeneron, LinkedIn at MarketWatch |
| 02:10PM | Regeneron Eyes 2 New Ophthalmology Treatments at Motley Fool |
| 01:55PM | Eylea Drives Earnings at Regeneron Zacks |
| 12:20PM | Regeneron Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 01-May-13 08:30PM | Why Allergan's Pain Is Regeneron's Gain at Motley Fool +10.30% |
| 06:08PM | Nasdaq stocks posting largest percentage increases AP |
| 06:00PM | [video] Cramer's Thoughts on Wednesday's Decline at CNBC |
| 05:26PM | After the close: Allergan losses worsen, Humana gains on earnings at MarketWatch |
| 05:01PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 04:29PM | Forbes Earnings Preview: Regeneron Pharmaceuticals at Forbes |
| 04:11PM | Stocks Pull Back In Higher Turnover, But Regeneron Soars at Investor's Business Daily |
| 04:00PM | [video] Tough Day for Stocks at CNBC |
| 03:58PM | Regeneron Soars To New High On Allergan's Test Delays at Investor's Business Daily |
| 03:39PM | Allergan slides, Regeneron surges on eye drug news AP |
| 02:51PM | Allergan shares fall on delay of eye drug study AP |
| 01:18PM | Nasdaq stocks posting largest percentage increases AP |
| 01:12PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 11:51AM | Allergan falls, Regeneron jumps on speculation over vision-loss drug at MarketWatch |
| 11:48AM | Regeneron surges after Allergan says vision-loss drug delayed at theflyonthewall.com |
| 11:46AM | Analyst Moves: ECL, ESRX, REGN at Forbes |
| 11:17AM | BRIEF-Regeneron Pharma shares resume trading, up 16 percent at Reuters |
| 11:16AM | BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3 at Reuters |
| 11:11AM | Allergan falls, Regeneron jumps after Allergan comments on drug trial at theflyonthewall.com |
| 11:11AM | BRIEF-Regeneron Pharma shares halted, last up 14.3 pct at Reuters |
| 11:07AM | Regeneron halted for volatility after spiking 14% to $245.90 theflyonthewall.com |
| 10:43AM | Regeneron Stock Hits New 52-Week High (REGN) at TheStreet |
| 09:53AM | [video] Cramer's Six in 60: Humana, 'Best of Breed' at CNBC |
| 30-Apr-13 11:28AM | Making the Call to Come Back to Biotech: An Expert Analyst Discusses His Positive Outlook on the Biotech Sector with The Wall Street Transcript Wall Street Transcript |
| 07:10AM | 3 Biotech Companies Ripe for a Takeover at Motley Fool |
| 29-Apr-13 08:08PM | Wall Street Gets It Backward On Amgen Cholesterol Drug at Forbes |
| 12:38PM | Analyst Moves: WYNN, VFC, REGN at Forbes |
| 26-Apr-13 11:49AM | Mark A. Emalfarb, Founder, Chairman, President and CEO of Dyadic International (DYAI), Interviews with The Wall Street Transcript Wall Street Transcript |
| 11:24AM | My top stock pick at MarketWatch |
| 10:52AM | Is biotech rally for real this time? at MarketWatch |
| 04:18AM | My Number One Ranked Stock at Seeking Alpha |
| 25-Apr-13 05:00PM | Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Winner at TheStreet |
| 08:41AM | Early Movers: XOM, MMM, UPS & More at CNBC |
|
|
| Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BROWN MICHAEL S | Director | May 17 | Sale | 269.02 | 5,000 | 1,345,120 | 14,662 | May 17 02:37 PM | | BROWN MICHAEL S | Director | May 15 | Option Exercise | 24.41 | 15,000 | 366,150 | 29,662 | May 17 02:37 PM | | BROWN MICHAEL S | Director | May 15 | Sale | 278.28 | 10,000 | 2,782,800 | 19,662 | May 17 02:37 PM | | Aberman Michael S | VP Strategy and Investor Relat | May 14 | Sale | 279.61 | 5,529 | 1,545,960 | 11,700 | May 15 05:04 PM | | Aberman Michael S | VP Strategy and Investor Relat | May 13 | Option Exercise | 24.00 | 12,500 | 300,000 | 24,200 | May 15 05:04 PM | | STAHL NEIL | SVP Research and Development S | May 13 | Sale | 276.88 | 23,038 | 6,378,806 | 48,988 | May 14 11:51 AM | | SING GEORGE L | Director | May 10 | Option Exercise | 15.01 | 5,000 | 75,050 | 117,772 | May 10 04:19 PM | | STAHL NEIL | SVP Research and Development S | May 10 | Option Exercise | 21.92 | 55,438 | 1,215,201 | 104,426 | May 14 11:51 AM | | SING GEORGE L | Director | May 10 | Sale | 270.00 | 5,000 | 1,350,000 | 112,772 | May 10 04:19 PM | | Terifay Robert J | SVP Commercial | May 08 | Sale | 261.23 | 8,231 | 2,150,192 | 15,324 | May 09 04:59 PM | | Terifay Robert J | SVP Commercial | May 07 | Option Exercise | 16.80 | 16,923 | 284,306 | 30,074 | May 09 04:59 PM | | YANCOPOULOS GEORGE | President Regeneron Laboratori | May 07 | Sale | 262.64 | 100,000 | 26,263,581 | 1,106,395 | May 08 05:49 PM | | Van Plew Daniel P | SVP & General Mgr Industrial O | May 07 | Sale | 261.61 | 13,725 | 3,590,637 | 10,736 | May 08 05:51 PM | | YANCOPOULOS GEORGE | President Regeneron Laboratori | May 06 | Option Exercise | 13.00 | 192,308 | 2,500,004 | 1,309,638 | May 08 05:49 PM | | Tessier-Lavigne Marc | Director | May 06 | Option Exercise | 53.23 | 13,334 | 709,834 | 8,334 | May 08 05:52 PM | | Van Plew Daniel P | SVP & General Mgr Industrial O | May 06 | Option Exercise | 16.80 | 32,950 | 553,560 | 39,784 | May 08 05:51 PM | | SHOOTER ERIC M | Director | May 06 | Option Exercise | 37.09 | 20,000 | 741,800 | 5,039 | May 08 05:53 PM | | GILMAN ALFRED G | Director | May 06 | Option Exercise | 21.77 | 30,000 | 652,950 | 9,600 | May 08 05:54 PM | | Aberman Michael S | VP Strategy and Investor Relat | May 06 | Option Exercise | 24.00 | 8,334 | 200,016 | 18,434 | May 08 05:55 PM | | VAGELOS P ROY | Chairman of the Board | May 06 | Sale | 263.21 | 13,482 | 3,548,550 | 114,018 | May 08 05:50 PM | | Tessier-Lavigne Marc | Director | May 06 | Sale | 260.91 | 13,334 | 3,478,942 | 0 | May 08 05:52 PM | | SHOOTER ERIC M | Director | May 06 | Sale | 259.36 | 20,000 | 5,187,224 | 0 | May 08 05:53 PM | | SHOOTER ERIC M | Director | May 06 | Sale | 261.96 | 10,000 | 2,619,648 | 2,500 | May 08 05:53 PM | | GILMAN ALFRED G | Director | May 06 | Sale | 261.04 | 30,000 | 7,831,302 | 0 | May 08 05:54 PM | | Aberman Michael S | VP Strategy and Investor Relat | May 06 | Sale | 257.13 | 8,334 | 2,142,927 | 11,700 | May 08 05:55 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | May 02 | Sale | 244.79 | 2,213 | 541,725 | 4,000 | May 03 04:09 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | May 01 | Option Exercise | 52.03 | 5,875 | 305,676 | 9,875 | May 03 04:09 PM | | SCHLEIFER LEONARD S | President & CEO | May 01 | Sale | 237.65 | 100,000 | 23,765,289 | 42,087 | May 03 04:09 PM | | McCorkle Douglas S | VP Controller and Asst Treasur | Apr 12 | Sale | 211.01 | 3,129 | 660,235 | 4,000 | Apr 16 12:39 PM | | McCorkle Douglas S | VP Controller and Asst Treasur | Apr 11 | Option Exercise | 30.63 | 5,875 | 179,951 | 9,875 | Apr 16 12:39 PM | | GOLDSTEIN JOSEPH L | Director | Apr 01 | Option Exercise | 24.41 | 5,000 | 122,050 | 5,000 | Apr 02 09:23 AM | | GOLDSTEIN JOSEPH L | Director | Apr 01 | Sale | 180.00 | 5,000 | 900,000 | 0 | Apr 02 09:23 AM | | BROWN MICHAEL S | Director | Mar 21 | Option Exercise | 18.61 | 15,000 | 279,150 | 21,422 | Mar 22 04:32 PM | | BROWN MICHAEL S | Director | Mar 21 | Sale | 173.27 | 15,000 | 2,599,022 | 14,662 | Mar 22 04:32 PM | | SCHLEIFER LEONARD S | President & CEO | Mar 19 | Sale | 175.02 | 3,655 | 639,698 | 142,087 | Mar 21 04:18 PM | | SCHLEIFER LEONARD S | President & CEO | Mar 13 | Sale | 175.01 | 4,662 | 815,897 | 145,742 | Mar 15 05:03 PM | | SCHLEIFER LEONARD S | President & CEO | Mar 07 | Sale | 175.13 | 3,534 | 618,909 | 150,404 | Mar 07 05:08 PM | | SCHLEIFER LEONARD S | President & CEO | Mar 06 | Sale | 175.38 | 69,003 | 12,101,570 | 153,938 | Mar 07 05:08 PM | | SCHLEIFER LEONARD S | President & CEO | Mar 05 | Sale | 175.21 | 19,146 | 3,354,571 | 222,941 | Mar 07 05:08 PM | | SHOOTER ERIC M | Director | Feb 26 | Sale | 160.00 | 10,000 | 1,600,000 | 2,500 | Feb 28 02:32 PM | | GOLDBERG MURRAY A | SVP Finance and Admin CFO Trea | Jan 16 | Sale | 172.16 | 7,878 | 1,356,272 | 58,592 | Jan 17 04:30 PM | | GOLDSTEIN JOSEPH L | Director | Jan 09 | Option Exercise | 57.11 | 5,000 | 285,550 | 5,000 | Jan 09 05:13 PM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Jan 09 | Option Exercise | 17.38 | 5,752 | 99,980 | 20,742 | Jan 10 09:25 AM | | GOLDSTEIN JOSEPH L | Director | Jan 09 | Sale | 185.00 | 5,000 | 925,000 | 0 | Jan 09 05:13 PM | | GOLDSTEIN JOSEPH L | Director | Jan 04 | Option Exercise | 33.42 | 5,000 | 167,100 | 2,740 | Jan 07 10:02 AM | | GOLDSTEIN JOSEPH L | Director | Jan 04 | Sale | 180.83 | 5,000 | 904,127 | 0 | Jan 07 10:02 AM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Jan 03 | Sale | 182.11 | 13,586 | 2,474,091 | 14,990 | Jan 04 10:00 AM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Jan 02 | Option Exercise | 21.25 | 30,000 | 637,500 | 44,990 | Jan 04 10:00 AM | | Van Plew Daniel P | SVP & Gen Mgr IOPS | Dec 20 | Option Exercise | 16.80 | 2,050 | 34,440 | 6,834 | Dec 21 03:17 PM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Dec 20 | Sale | 170.64 | 6,623 | 1,130,164 | 14,990 | Dec 20 04:17 PM | | YANCOPOULOS GEORGE | EVP CSO Pres Regen Res Labs | Dec 19 | Option Exercise | 13.77 | 50,846 | 699,978 | 1,117,330 | Dec 21 03:11 PM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Dec 19 | Sale | 178.50 | 10,356 | 1,848,536 | 21,613 | Dec 20 04:17 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | Dec 19 | Sale | 175.44 | 1,841 | 322,986 | 4,000 | Dec 20 04:16 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | Dec 18 | Option Exercise | 21.25 | 4,625 | 98,281 | 7,873 | Dec 20 04:16 PM | | Aberman Michael S | VP Strategy and Investor Relat | Dec 18 | Option Exercise | 24.00 | 1,200 | 28,800 | 11,700 | Dec 19 04:24 PM | | Terifay Robert J | SVP Commercial | Dec 18 | Option Exercise | 16.80 | 5,952 | 99,994 | 15,324 | Dec 19 04:23 PM | | Powchik Peter | SVP Clin Devel & Reg Affairs | Dec 18 | Option Exercise | 31.61 | 38,248 | 1,209,090 | 39,446 | Dec 20 04:17 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | Dec 18 | Sale | 179.00 | 752 | 134,606 | 5,841 | Dec 20 04:16 PM | | McCorkle Douglas S | VP Controller & Asst Treasurer | Dec 17 | Option Exercise | 16.80 | 5,000 | 84,000 | 4,800 | Dec 18 11:31 AM | | STAHL NEIL | SVP Res and Devel Sciences | Dec 17 | Option Exercise | 16.80 | 5,952 | 99,994 | 48,988 | Dec 18 11:31 AM | | GOLDBERG MURRAY A | SVP Fin & Admin CFO Asst Secy | Dec 17 | Option Exercise | 20.32 | 1,850 | 37,592 | 66,470 | Dec 18 11:34 AM | | YANCOPOULOS GEORGE | EVP CSO Pres Regen Res Labs | Dec 17 | Option Exercise | 109.29 | 10,369 | 1,133,228 | 1,304,811 | Dec 18 11:33 AM | | McCorkle Douglas S | VP Controller & Asst Treasurer | Dec 17 | Sale | 179.20 | 1,000 | 179,198 | 4,000 | Dec 18 11:31 AM | | Aberman Michael S | VP Strategy and Investor Relat | Dec 11 | Sale | 185.06 | 3,368 | 623,268 | 10,500 | Dec 12 09:34 AM | | Aberman Michael S | VP Strategy and Investor Relat | Dec 10 | Option Exercise | 30.63 | 7,500 | 229,725 | 18,000 | Dec 12 09:34 AM | | STAHL NEIL | SVP Res and Devel Sciences | Nov 30 | Option Exercise | 21.09 | 9,483 | 199,994 | 51,422 | Dec 03 04:20 PM | | ROBERTS WILLIAM | VP Regulat Dev & Med Safety | Nov 30 | Sale | 180.78 | 11,500 | 2,078,975 | 0 | Dec 04 04:09 PM | | Aberman Michael S | VP Strategy and Investor Relat | Nov 30 | Sale | 180.64 | 3,904 | 705,228 | 10,500 | Dec 03 04:21 PM | | STAHL NEIL | SVP Res and Devel Sciences | Nov 30 | Sale | 181.01 | 17,182 | 3,110,114 | 41,939 | Dec 03 04:20 PM | | Aberman Michael S | VP Strategy and Investor Relat | Nov 29 | Option Exercise | 24.00 | 8,334 | 200,016 | 18,834 | Dec 03 04:21 PM | | VAGELOS P ROY | Chairman of the Board | Nov 29 | Sale | 179.47 | 78,630 | 14,111,468 | 56,946 | Nov 30 01:47 PM | | SING GEORGE L | Director | Nov 29 | Sale | 185.00 | 5,000 | 925,000 | 122,772 | Nov 29 01:30 PM | | VAGELOS P ROY | Chairman of the Board | Nov 28 | Sale | 175.03 | 7,004 | 1,225,910 | 135,576 | Nov 30 01:47 PM | | VAGELOS P ROY | Chairman of the Board | Nov 27 | Sale | 175.30 | 36,246 | 6,353,788 | 142,580 | Nov 27 06:23 PM | | BAKER CHARLES A | Director | Nov 26 | Option Exercise | 9.17 | 15,000 | 137,550 | 16,155 | Nov 27 05:54 PM | | VAGELOS P ROY | Chairman of the Board | Nov 26 | Sale | 175.12 | 28,507 | 4,992,146 | 178,826 | Nov 27 06:23 PM | | BAKER CHARLES A | Director | Nov 26 | Sale | 173.87 | 15,000 | 2,607,986 | 9,590 | Nov 27 05:54 PM | | VAGELOS P ROY | Chairman of the Board | Nov 23 | Option Exercise | 19.43 | 312,500 | 6,071,875 | 369,446 | Nov 27 06:23 PM | | Terifay Robert J | SVP Commercial | Nov 23 | Sale | 174.45 | 9,745 | 1,699,970 | 9,372 | Nov 26 03:39 PM | | Terifay Robert J | SVP Commercial | Nov 21 | Option Exercise | 16.80 | 20,000 | 336,000 | 29,372 | Nov 26 03:39 PM | | STAHL NEIL | SVP Res and Devel Sciences | Nov 21 | Sale | 174.30 | 24,357 | 4,245,442 | 59,121 | Nov 21 03:50 PM | | STAHL NEIL | SVP Res and Devel Sciences | Nov 20 | Option Exercise | 16.80 | 54,500 | 915,600 | 104,219 | Nov 21 03:50 PM | | VAGELOS P ROY | Chairman of the Board | Nov 19 | Sale | 160.61 | 32,500 | 5,219,974 | 127,500 | Nov 20 09:50 AM | | SCHLEIFER LEONARD S | President & CEO | Nov 16 | Option Exercise | 111.01 | 43,757 | 4,857,465 | 338,920 | Nov 19 05:25 PM | | SING GEORGE L | Director | Nov 16 | Sale | 152.00 | 5,000 | 760,000 | 127,772 | Nov 20 04:14 PM | | Van Plew Daniel P | SVP & General Mgr Industrial O | Nov 16 | Sale | 155.70 | 18,741 | 2,917,899 | 4,784 | Nov 16 05:03 PM | | BROWN MICHAEL S | Director | Nov 14 | Option Exercise | 23.84 | 7,000 | 166,880 | 21,662 | Nov 15 10:26 AM | | GOLDBERG MURRAY A | SVP Finance and Admin CFO Trea | Nov 14 | Sale | 148.27 | 3,156 | 467,954 | 83,977 | Nov 15 05:12 PM | | BROWN MICHAEL S | Director | Nov 14 | Sale | 147.03 | 7,000 | 1,029,210 | 14,662 | Nov 15 10:26 AM | | GOLDBERG MURRAY A | SVP Finance and Admin CFO Trea | Nov 13 | Option Exercise | 41.73 | 8,176 | 341,195 | 95,357 | Nov 15 05:12 PM | | SING GEORGE L | Director | Nov 13 | Sale | 148.00 | 5,000 | 740,000 | 132,772 | Nov 15 05:13 PM | | GOLDBERG MURRAY A | SVP Finance and Admin CFO Trea | Nov 13 | Sale | 147.26 | 6,537 | 962,634 | 87,133 | Nov 15 05:12 PM | | Powchik Peter | SVP Clinical Development & Reg | Nov 08 | Sale | 138.62 | 15,144 | 2,099,221 | 14,990 | Nov 09 10:27 AM | | RYAN ARTHUR F | Director | Nov 01 | Sale | 145.57 | 10,000 | 1,455,700 | 40,355 | Nov 05 10:14 AM | | BROWN MICHAEL S | Director | Oct 26 | Option Exercise | 23.84 | 3,000 | 71,520 | 17,662 | Oct 26 03:43 PM | | BROWN MICHAEL S | Director | Oct 26 | Sale | 154.69 | 3,000 | 464,070 | 14,662 | Oct 26 03:43 PM | | BROWN MICHAEL S | Director | Oct 25 | Option Exercise | 23.84 | 2,000 | 47,680 | 16,662 | Oct 26 03:43 PM | | Van Plew Daniel P | SVP & General Mgr Industrial O | Oct 25 | Option Exercise | 21.92 | 30,000 | 657,600 | 39,568 | Oct 26 05:50 PM | | BROWN MICHAEL S | Director | Oct 25 | Sale | 155.34 | 2,000 | 310,680 | 14,662 | Oct 26 03:43 PM | | BAKER CHARLES A | Director | Sep 06 | Option Exercise | 15.01 | 13,714 | 205,847 | 23,304 | Sep 06 03:34 PM |
|
|
|
|
|
|
